There are currently 83 active clinical trials seeking participants for Myelodysplastic Syndromes research studies. The states with the highest number of trials for Myelodysplastic Syndromes participants are Ohio, California, New York and Texas.
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
NCT05031897
Recruiting
This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other forms of treatment. In recent years, less intense conditioning regimens with radiation and chemotherapy prior to HSCT have been developed. Radiation... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndromes, Myelofibrosis, Myeloid Leukemia, Myeloid Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Polycythemia Vera, Small Lymphocytic Lymphoma
Register for Updates
IS-free Treg HaploHCT
NCT04678401
Recruiting
This research study is evaluating the safety and efficacy of the IS-free Treg-cell graft-engineered haplo transplant method in people with relapsed/refractory and Ultra-high risk acute myeloid leukemia (AML) and/or myelodysplastic syndromes (MDS) receiving a haploidentical donor allogeneic hematopoietic stem cell transplant (HSCT). The names of the study interventions involved in this study are: Radiation-Total Myeloid and Lymphoid Irradiation (TMLI Chemotherapy (Fludarabine, Thiotepa, Cycloph... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/02/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute, Myeloid Leukemia in Relapse (Disorder), Myelodysplastic Syndromes
Register for Updates
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
NCT04986657
Recruiting
This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnoses of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Gender:
All
Ages:
18 years and above
Trial Updated:
12/04/2023
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Whole Genome Sequencing, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
NCT05194397
Recruiting
This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors. The primary outcome is the change in muscle strength (isometric knee extension) from baseline to 16 weeks. Key secondary outcomes are the change in muscle strength (ankle plantarflexion) from baseline to 16 weeks, the change in grip strength from baseline to 16 weeks, the change in lower extremity m... Read More
Gender:
All
Ages:
Between 10 years and 30 years
Trial Updated:
11/16/2023
Locations: City of Hope Medical Center, Duarte, California +2 locations
Conditions: Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes, Lymphoblastic Leukemia
Register for Updates
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130
Recruiting
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2023
Locations: City of Hope National Medical Center, Duarte, California +40 locations
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
Register for Updates
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
NCT01137643
Recruiting
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
10/16/2023
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina
Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Register for Updates
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
NCT04539236
Recruiting
The purpose of this study is to evaluate if the combination of drugs, Lenalidomide and Luspatercept, will help improve the treatment of anemia in patients with lower-risk Myelodysplastic Syndrome (MDS).
Gender:
All
Ages:
18 years and above
Trial Updated:
09/29/2023
Locations: University of Miami, Miami, Florida +5 locations
Conditions: Myelodysplastic Syndromes
Register for Updates
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
NCT04742634
Recruiting
The investigators hypothesize that early measurable residual disease (MRD)-guided pre-emptive therapy with decitabine + cedazaridine (DEC-C) will decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS) patients with persistent mutations (molecular MRD). To detect molecular MRD, the investigators will perform ultra-deep, error-corrected panel-based sequencing (MyeloSeq-HD) at Day 30 in post-transplant MDS patients. The investigators will treat patients with detectable... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/02/2023
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Myelodysplastic Syndromes
Register for Updates
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
NCT05434598
Recruiting
This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnosis of myelodysplastic syndrome (MDS).
Gender:
All
Ages:
18 years and above
Trial Updated:
09/02/2023
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Whole Genome Sequencing, Myelodysplastic Syndromes
Register for Updates
AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
NCT04263181
Recruiting
In this study, the investigators will explore the feasibility of ex vivo drug screening to predict sensitivity to chemotherapy resistance and to identify novel synergy between chemotherapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/10/2023
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
NTX-301 in MDS/AML
NCT04167917
Recruiting
NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies.
Gender:
Male
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +1 locations
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Register for Updates
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
NCT05455294
Recruiting
The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies. The names of the drugs involved in this study are: Venetoclax Decitabine Navitoclax
Gender:
All
Ages:
18 years and above
Trial Updated:
07/24/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts +2 locations
Conditions: Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia, Myeloproliferative Neoplasm
Register for Updates